Tempest Therapeutics Inc (TPST)

$1.92 -0.02 (-1.03%)
Market Cap 27.83M
Revenue (ttm) 0.00
Net Income (ttm) -26.26M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 61,100
Avg Vol 223,006
Day's Range N/A - N/A
Shares Out 14.34M
Stochastic %K 41%
Beta -1.75
Analysts Strong Sell
Price Target $11.00

Company Profile

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating va...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 798 8589
Address:
2000 Sierra Point Parkway, Suite 400, Brisbane, United States
MoneyorBagHolder
MoneyorBagHolder May. 13 at 12:41 PM
$TPST I am seeing Tuesday May 26 after hours as Q1 2026 earning release. Is anyone seeing any other day/time? If more time is needed to have a better update on the product pipeline and other, I am ok with the wait.
1 · Reply
MoneyorBagHolder
MoneyorBagHolder May. 12 at 10:17 PM
$TPST If there is going to be a moneymaker at Tempest Therapeutics in the “near term” is arguably from Amezalpat (TPST-1120). I am seeing this Wednesday May 13 earning release premarket. My expectation, given that the CEO had done the half a mill purchase at $2.16 per share, that some update is due on who was selected or how close in selecting or finalizing business development partnership or licensing deal for TPST-1120. Correct if am wrong, but didn’t Tempest Therapeutics hired a Head of Business Development to advance the pivotal Phase 3 program? I am using the phrase near term in comparison that other product candidates are far away like TPST-2003 and TPST-1495. I think TPST-2206, TPST-3003, TPST-3206, and TPST-4003 that are in Discovery or Preclinical stage indicates to me that either Tempest Therapeutics has the potential on becoming a pioneer in its industry or a company that basically just cares about the research and having offerings and RS, or something else.
1 · Reply
fantastex
fantastex May. 12 at 8:36 PM
$TPST we are close.
1 · Reply
Xamayca
Xamayca May. 12 at 6:16 PM
$TPST Otcis interesting considering it was just over a year ago they TPST retained the investment bank to over see the sale of the legacy assets and proceeded to set up authorization for EMEA and Chinese market the out come was not an outright sale of assets but rather a merger which expanded the pipeline and extended the lifeline financially, now we have investment from a Chinese connected deep pocketed pharma entrepreneurial organization, essentially funding was provided and a handover was executed in the person of Dr. Fang one has to believe potential China deals were discussed and perhaps to some extent consummated contingent on certain milestones and occurrences. I do t think we need another investment bank partner to solicit buyers for the legacy molecules. I believe that legwork has already been completed and Dr. Fang will wrap up the sale JMHO!
2 · Reply
Michl2000
Michl2000 May. 12 at 3:33 PM
$TPST worst shitty stock development, i've ever seen. meanwhile brady gets fatter and fatter
0 · Reply
Michl2000
Michl2000 May. 12 at 3:22 PM
$TPST 💩💩💩
0 · Reply
WitchKingOfAngmar
WitchKingOfAngmar May. 11 at 6:25 PM
$TPST I got excited when we closed above the 50ema last week thinking this was going to make a move. Bad thinking. The markets mm's did what they always do on companies like this, defend a moving average and not let it run. I know they have loaded this with fake air shares. I see it in the trading and how others have faired. Illegal as fk, but the gov don't gas either. How they are going to claw their way out of this, I got no idea. Never give up watching, but not looking for anything soon.
1 · Reply
Michl2000
Michl2000 May. 11 at 5:33 PM
$TPST
0 · Reply
Michl2000
Michl2000 May. 11 at 5:31 PM
$TPST 💩💩💩
0 · Reply
Michl2000
Michl2000 May. 11 at 5:16 PM
$TPST 😱😭😱
0 · Reply
Latest News on TPST
Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

May 6, 2026, 7:00 AM EDT - 7 days ago

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting

Apr 29, 2026, 8:00 AM EDT - 14 days ago

Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting

Tempest Therapeutics provides update on development of TPST-2003

2026-04-22T12:30:21.000Z - 21 days ago

Tempest Therapeutics provides update on development of TPST-2003

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

Apr 22, 2026, 8:00 AM EDT - 21 days ago

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts

Apr 14, 2026, 8:00 AM EDT - 4 weeks ago

Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts

Tempest Therapeutics files to sell 2.78M shares of common stock for holders

2026-04-02T10:11:28.000Z - 5 weeks ago

Tempest Therapeutics files to sell 2.78M shares of common stock for holders

Tempest Therapeutics files to sell 8.27M shares of common stock for holders

2026-03-30T22:05:33.000Z - 6 weeks ago

Tempest Therapeutics files to sell 8.27M shares of common stock for holders

Tempest Reports Year End 2025 Financial Results and Provides Business Update

Mar 30, 2026, 9:00 AM EDT - 6 weeks ago

Tempest Reports Year End 2025 Financial Results and Provides Business Update

Tempest Therapeutics Announces Up To $6 Million Private Placement

Mar 23, 2026, 8:00 AM EDT - 7 weeks ago

Tempest Therapeutics Announces Up To $6 Million Private Placement

Tempest, Cincinnati Children’s AGCTC partner for TPST-2003 registrational study

2026-03-11T12:06:24.000Z - 2 months ago

Tempest, Cincinnati Children’s AGCTC partner for TPST-2003 registrational study

Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026

Mar 11, 2026, 8:00 AM EDT - 2 months ago

Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026

Tempest Therapeutics announces data from REDEEM-1 Phase 1/2a trial on TPST-2003

2026-02-25T13:24:11.000Z - 2 months ago

Tempest Therapeutics announces data from REDEEM-1 Phase 1/2a trial on TPST-2003

Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026

Feb 25, 2026, 7:59 AM EST - 2 months ago

Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026

Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets

Feb 11, 2026, 6:59 AM EST - 3 months ago

Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets

Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets

Feb 4, 2026, 4:47 PM EST - 3 months ago

Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets

Tempest Therapeutics upgraded to Buy from Neutral at H.C. Wainwright

2026-01-22T11:12:02.000Z - 3 months ago

Tempest Therapeutics upgraded to Buy from Neutral at H.C. Wainwright

Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders

Jan 20, 2026, 5:20 PM EST - 4 months ago

Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders

Tempest Therapeutics files to sell 1.17M shares of common stock for holders

2025-12-09T21:55:14.000Z - 5 months ago

Tempest Therapeutics files to sell 1.17M shares of common stock for holders

Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

Nov 26, 2025, 4:05 PM EST - 5 months ago

Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

Tempest Therapeutics prices 1.17M shares at $3.63 in registered direct offering

2025-11-25T13:05:18.000Z - 6 months ago

Tempest Therapeutics prices 1.17M shares at $3.63 in registered direct offering

Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

Nov 25, 2025, 8:00 AM EST - 6 months ago

Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

Tempest announces acquisition of new dual-CAR T programs from Factor Bioscience

2025-11-19T14:11:00.000Z - 6 months ago

Tempest announces acquisition of new dual-CAR T programs from Factor Bioscience

Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027

Nov 19, 2025, 9:00 AM EST - 6 months ago

Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027

BTX

Tempest Therapeutics reports Q3 EPS (79c) vs ($5.32) last year

2025-11-05T13:36:56.000Z - 6 months ago

Tempest Therapeutics reports Q3 EPS (79c) vs ($5.32) last year

Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 5, 2025, 8:30 AM EST - 6 months ago

Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update

Tempest Therapeutics reports Q2 EPS ($2.07), consensus ($2.65)

2025-08-11T20:55:19.000Z - 9 months ago

Tempest Therapeutics reports Q2 EPS ($2.07), consensus ($2.65)

Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 11, 2025, 4:12 PM EDT - 9 months ago

Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update

Tempest Therapeutics receives NMPA clearance to proceed with amezalpat trial

2025-06-30T14:37:56.000Z - 11 months ago

Tempest Therapeutics receives NMPA clearance to proceed with amezalpat trial

Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

Jun 30, 2025, 8:00 AM EDT - 11 months ago

Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

Tempest prices 739,000 shares at $6.25 in registered direct offering

2025-06-11T12:20:36.000Z - 1 year ago

Tempest prices 739,000 shares at $6.25 in registered direct offering

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

Jun 11, 2025, 8:00 AM EDT - 1 year ago

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

Tempest Therapeutics receives ODD from EMA for amezalpat

2025-06-05T12:05:21.000Z - 1 year ago

Tempest Therapeutics receives ODD from EMA for amezalpat

Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC

Jun 5, 2025, 8:00 AM EDT - 1 year ago

Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC

Tempest Therapeutics reports Q1 EPS ($3.16), consensus ($3.29)

2025-05-13T20:35:15.000Z - 1 year ago

Tempest Therapeutics reports Q1 EPS ($3.16), consensus ($3.29)

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025, 4:28 PM EDT - 1 year ago

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

Apr 28, 2025, 4:05 PM EDT - 1 year ago

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

Tempest Therapeutics announces FDA granted ODD to TPST-1495

2025-04-21T12:08:31.000Z - 1 year ago

Tempest Therapeutics announces FDA granted ODD to TPST-1495

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

Apr 9, 2025, 4:30 PM EDT - 1 year ago

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

Tempest Reports Year End 2024 Financial Results and Provides Business Update

Mar 27, 2025, 4:10 PM EDT - 1 year ago

Tempest Reports Year End 2024 Financial Results and Provides Business Update

Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

Mar 13, 2025, 8:00 AM EDT - 1 year ago

FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

Feb 10, 2025, 8:00 AM EST - 1 year ago

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 7, 2025, 4:30 PM EST - 1 year ago

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

Jan 6, 2025, 8:00 AM EST - 1 year ago

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

Tempest Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 9:00 AM EST - 1 year ago

Tempest Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 25, 2024, 4:30 PM EST - 1 year ago

Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 12, 2024, 4:21 PM EST - 1 year ago

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

Oct 10, 2024, 7:01 AM EDT - 1 year ago

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 20, 2024, 4:30 PM EDT - 1 year ago

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tempest Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Tempest Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 5, 2024, 8:00 AM EDT - 1 year ago

Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma

Aug 15, 2024, 8:00 AM EDT - 1 year ago

Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma

Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 8, 2024, 4:56 PM EDT - 1 year ago

Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update

Tempest Therapeutics Transcript: Study Update

Jun 20, 2024, 8:30 AM EDT - 2 years ago

Tempest Therapeutics Transcript: Study Update

Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma

Jun 18, 2024, 6:22 PM EDT - 2 years ago

Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma

Tempest Therapeutics Transcript: Jefferies Global Healthcare Conference

Jun 5, 2024, 4:00 PM EDT - 2 years ago

Tempest Therapeutics Transcript: Jefferies Global Healthcare Conference

Tempest Therapeutics Transcript: TD Cowen 5th Annual Oncology Innovation Virtual Summit

May 29, 2024, 2:00 PM EDT - 2 years ago

Tempest Therapeutics Transcript: TD Cowen 5th Annual Oncology Innovation Virtual Summit

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 4:29 PM EDT - 2 years ago

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

Apr 9, 2024, 8:00 AM EDT - 2 years ago

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

Apr 4, 2024, 8:00 AM EDT - 2 years ago

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

Tempest Reports Year End 2023 Financial Results and Provides Business Update

Mar 19, 2024, 4:25 PM EDT - 2 years ago

Tempest Reports Year End 2023 Financial Results and Provides Business Update

Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting

Mar 5, 2024, 4:30 PM EST - 2 years ago

Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting

Tempest Therapeutics Transcript: TD Cowen 44th Annual Health Care Conference 2024

Mar 4, 2024, 9:10 AM EST - 2 years ago

Tempest Therapeutics Transcript: TD Cowen 44th Annual Health Care Conference 2024

Tempest Therapeutics Transcript: Piper Sandler 35th Annual Healthcare Conference

Nov 28, 2023, 3:00 PM EST - 2 years ago

Tempest Therapeutics Transcript: Piper Sandler 35th Annual Healthcare Conference

Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 20, 2023, 8:00 AM EST - 2 years ago

Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference

Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 8, 2023, 5:17 PM EST - 2 years ago

Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update

Tempest Therapeutics shares end wild week with 8% drop

Oct 13, 2023, 4:13 PM EDT - 2 years ago

Tempest Therapeutics shares end wild week with 8% drop

Tempest Therapeutics shares head back to earth after 4,000% gain

Oct 12, 2023, 12:49 PM EDT - 2 years ago

Tempest Therapeutics shares head back to earth after 4,000% gain

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

Oct 12, 2023, 11:26 AM EDT - 2 years ago

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

ANVS AVTX MTNB

Tempest Therapeutics' stock jumps 1,900% as liver-cancer treatment shows promise

Oct 11, 2023, 12:29 PM EDT - 2 years ago

Tempest Therapeutics' stock jumps 1,900% as liver-cancer treatment shows promise

Tempest Therapeutics Transcript: Study Result

Oct 11, 2023, 8:30 AM EDT - 2 years ago

Tempest Therapeutics Transcript: Study Result

Tempest Adopts Limited Duration Stockholder Rights Plan

Oct 11, 2023, 8:01 AM EDT - 2 years ago

Tempest Adopts Limited Duration Stockholder Rights Plan

MoneyorBagHolder
MoneyorBagHolder May. 13 at 12:41 PM
$TPST I am seeing Tuesday May 26 after hours as Q1 2026 earning release. Is anyone seeing any other day/time? If more time is needed to have a better update on the product pipeline and other, I am ok with the wait.
1 · Reply
MoneyorBagHolder
MoneyorBagHolder May. 12 at 10:17 PM
$TPST If there is going to be a moneymaker at Tempest Therapeutics in the “near term” is arguably from Amezalpat (TPST-1120). I am seeing this Wednesday May 13 earning release premarket. My expectation, given that the CEO had done the half a mill purchase at $2.16 per share, that some update is due on who was selected or how close in selecting or finalizing business development partnership or licensing deal for TPST-1120. Correct if am wrong, but didn’t Tempest Therapeutics hired a Head of Business Development to advance the pivotal Phase 3 program? I am using the phrase near term in comparison that other product candidates are far away like TPST-2003 and TPST-1495. I think TPST-2206, TPST-3003, TPST-3206, and TPST-4003 that are in Discovery or Preclinical stage indicates to me that either Tempest Therapeutics has the potential on becoming a pioneer in its industry or a company that basically just cares about the research and having offerings and RS, or something else.
1 · Reply
fantastex
fantastex May. 12 at 8:36 PM
$TPST we are close.
1 · Reply
Xamayca
Xamayca May. 12 at 6:16 PM
$TPST Otcis interesting considering it was just over a year ago they TPST retained the investment bank to over see the sale of the legacy assets and proceeded to set up authorization for EMEA and Chinese market the out come was not an outright sale of assets but rather a merger which expanded the pipeline and extended the lifeline financially, now we have investment from a Chinese connected deep pocketed pharma entrepreneurial organization, essentially funding was provided and a handover was executed in the person of Dr. Fang one has to believe potential China deals were discussed and perhaps to some extent consummated contingent on certain milestones and occurrences. I do t think we need another investment bank partner to solicit buyers for the legacy molecules. I believe that legwork has already been completed and Dr. Fang will wrap up the sale JMHO!
2 · Reply
Michl2000
Michl2000 May. 12 at 3:33 PM
$TPST worst shitty stock development, i've ever seen. meanwhile brady gets fatter and fatter
0 · Reply
Michl2000
Michl2000 May. 12 at 3:22 PM
$TPST 💩💩💩
0 · Reply
WitchKingOfAngmar
WitchKingOfAngmar May. 11 at 6:25 PM
$TPST I got excited when we closed above the 50ema last week thinking this was going to make a move. Bad thinking. The markets mm's did what they always do on companies like this, defend a moving average and not let it run. I know they have loaded this with fake air shares. I see it in the trading and how others have faired. Illegal as fk, but the gov don't gas either. How they are going to claw their way out of this, I got no idea. Never give up watching, but not looking for anything soon.
1 · Reply
Michl2000
Michl2000 May. 11 at 5:33 PM
$TPST
0 · Reply
Michl2000
Michl2000 May. 11 at 5:31 PM
$TPST 💩💩💩
0 · Reply
Michl2000
Michl2000 May. 11 at 5:16 PM
$TPST 😱😭😱
0 · Reply
Michl2000
Michl2000 May. 11 at 3:43 PM
$TPST 🥱🥱🥱
0 · Reply
lousjamsession
lousjamsession May. 11 at 1:32 PM
$TPST
1 · Reply
WeAllFallDown
WeAllFallDown May. 11 at 12:17 PM
$TPST Sideline Brady at the do nothing stature position so the science geeks can drive this one across the goal line...am I off?
0 · Reply
josegodoy
josegodoy May. 10 at 1:46 PM
$TPST we still in this ($2.30-$2.50) fight - we do need volume tho-
0 · Reply
Jaytil
Jaytil May. 9 at 2:28 PM
$TPST I’m looking backwardly and don’t have same perspective of longs, but I see the reverse merger as being a beneficial deal to both sides only if both sides brought value. Brady had what seems to be valuable legacy assets but looks like he was trying to sell them with no cash and no leverage. Angel and his backer Fang are in a lawsuit with AZ and wanted to spin their most promising assets to another entity so they “sell” them to Brady and get 60 percent of Brady’s company. Deal makes sense for Brady only because his legacy assets can yield more to him at 40 percent than at 100 percent ownership and makes sense for Angel/Fang bc their assets are de-risked and not in litigation and also because Brady’s legacy assets can now be sold at fair market value to fund 2003 development rather than depressed value because Fang the billionaire can fund it as long as he wants until someone pays a reasonable price. Win/win. This is my take.
2 · Reply
fantastex
fantastex May. 8 at 11:17 PM
$TPST 2.50 anytime.
0 · Reply
lousjamsession
lousjamsession May. 8 at 6:50 PM
$TPST
0 · Reply
Michl2000
Michl2000 May. 8 at 3:06 PM
$TPST 💩🥳🙈
0 · Reply
GJ_Rockabilt
GJ_Rockabilt May. 8 at 1:05 PM
$BURU We're still in $0.24+. I don't believe in magic numbers, but I made a lot of money on $TPST @ $0.24+.on October 11, 2023. Maybe others like that number, for whatever reason. HOLDING (again). Good thing I didn't SELL, back then, upon many s advise. I'm going to see what happens here. Oh, yes.
0 · Reply
CoffeeRocks
CoffeeRocks May. 7 at 6:32 PM
$ADVM $BTAI $CODX $TPST CODX 2$ running 🏃‍♂️
0 · Reply
lousjamsession
lousjamsession May. 7 at 5:04 PM
$TPST is currently a high-conviction clinical play following the massive data update at the ISCT Annual Meeting in Dublin this week. The company just reported a flawless 100% Complete Response (CR) rate across all 15 CAR-T-naïve patients in the REDEEM-1 and POEMS-1 trials, doubling their previous dataset while maintaining an industry-leading safety profile with zero Grade >3 CRS or ICANS. With a median PFS of 23.1 months and a manufacturing milestone already cleared for the lentiviral vector, the path to a pivotal registrational study in Q4 2026 is officially de-risked. When you factor in the strategic hire of Dr. Andrew Fang to lead global licensing and the Phase 3-ready status of amezalpat, the current market cap represents a massive disconnect from the science. Analysts like HC Wainwright are holding an $11.00 price target for a reason; with cash runway into mid-2027, the "dilution" bear case is dead, leaving nothing but a clinical runway for a best-in-class oncology asset.
3 · Reply
CoffeeRocks
CoffeeRocks May. 7 at 4:03 PM
$BTAI $ADVM $TPST $CODX Phase 3 SERENITY At Home data is an absolute monster. They tracked over 2,400 agitation episodes. For severe agitation, complete resolution hit 61% for BXCL501 versus just 18% for placebo with a p value of <0.0001. Overall resolution was 50% versus 33% (p < 0.0001). The efficacy is undeniable. This is an already approved drug expanding into a massive 86M episode market. PDUFA is locked for Nov 14. The science is completely de risked. Once management clears the financial overhang, there is zero resistance left. Loading up while the crowd is distracted.
0 · Reply